H1N1 vaccine trial in pregnant women set to begin soon in the U.S.

The randomised, double-blinded Phase II trial will enroll up to 120 women in the 18 to 39 age group, and who are in their second or third trimester (14 to 34 weeks) of pregnancy. The trial is expected to be completed by July 2010

Updated - November 17, 2021 06:54 am IST

Published - September 10, 2009 06:42 pm IST - CHENNAI:

The volunteers will receive either 15 micrograms or 30 micrograms of the candidate vaccine. The file photo a dose of the experimental vaccine for the H1N1 flu virus being prepared at Vanderbilt University Medical Center in Nashville, U.S. Photo: AP

The volunteers will receive either 15 micrograms or 30 micrograms of the candidate vaccine. The file photo a dose of the experimental vaccine for the H1N1 flu virus being prepared at Vanderbilt University Medical Center in Nashville, U.S. Photo: AP

The world’s first clinical trial of H1N1 influenza vaccine in pregnant women will be launched this week in the U.S. Pregnant women come under the at-risk category as they are at higher risk of developing severe illness if infected with the influenza virus. Pregnant women will be eligible to receive the vaccine on priority when it becomes available by the end of this month.

According to details available in the Clinicaltrials.gov (a clinical trial registry of the U.S.) site, up to 120 women in the 18 to 39-year age group and who are in their second or third trimester (14 to 34 weeks) of pregnancy will be enrolled in the trial.

The Sanofi Pasteur H1N1 influenza vaccine made from an inactivated virus will be used. Since it is an inactivated virus, the possibility of becoming infected by the virus does not arise. The vaccine will not contain an adjuvant — a substance added to a vaccine to improve the body's response to vaccine.

The randomised, double-blinded Phase II trial funded by the National Institute of Allergy and Infectious Diseases (NIAID), a government agency, will take place in six medical centres across the U.S. The trial is expected to be completed by July 2010.

The volunteers will receive either 15 micrograms or 30 micrograms of the candidate vaccine. All the volunteers will receive an initial injection and a second injection 21 days later.

The primary objective of the trial is to study the safety of the vaccine in pregnant women. The secondary objective is to assess the immune response after the first dose as well the second dose. The trial will also assess if a single dose will be sufficient to produce the desired immune response. If sufficient immune response is produced after the first dose, the vaccination programme will be restricted to just one shot.

The study will also measure maternal antibodies transferred to the infants through the placenta.

NIAID is planning to conduct additional trials in pregnant women testing candidate 2009 H1N1 influenza vaccines made by other manufacturers.

0 / 0
Sign in to unlock member-only benefits!
  • Access 10 free stories every month
  • Save stories to read later
  • Access to comment on every story
  • Sign-up/manage your newsletter subscriptions with a single click
  • Get notified by email for early access to discounts & offers on our products
Sign in

Comments

Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.

We have migrated to a new commenting platform. If you are already a registered user of The Hindu and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.